




FIGURE 1

FIGURE 2

SPA assay of [^3H]gabapentin (18.4nM) binding to s- $\alpha_2\delta$ -1b-6His (20 μl). Optimisation of Imidazole concentration in the assay.

**FIGURE 3**

Flashplate assay of [^3H]gabapentin (14nM) binding to s- $\alpha_2\delta$ -1b-6His (10 μl). Optimisation of Imidazole concentration in the assay.





FIGURE 4

Flashplate time course of [^3H]gabapentin (13nM) binding to various concentrations of s- $\alpha_2\delta$ -1b-6His.

**FIGURE 5**

Determination of s- $\alpha_2\delta$ -1b-6His capacity of flashplate assay. Counted after 3hour

20 incubation





FIGURE 6

Determination of the optimum imidazole concentration required to maximize the [^3H]gabapentin (13nM) binding window using a constant amount of purified s- $\alpha_2\delta$ -1b-6His (2 μl). Assayed after 3hour incubation.

**FIGURE 7**

Flashplate assay of [^3H]gabapentin saturation binding to purified s- $\alpha_2\delta$ -1b-6His. Assayed after three hour incubation (see table 1 for details).




Figure 8

Flashplate time course optimisation of Imidazole concentration required to maximize the

- 5 [^3H]Leucine (10.1nM) binding window to s- $\alpha_2\delta$ -1b-6His. Assayed after three hour incubation.





FIGURE 9

- 20 Competition curves of three compounds in the flashplate assay format (see table 2 for details). Assayed after 3 hour incubation.



- Gabapentin
- (S+)-3-isobutyl GABA
- ▼ (R-)-3-isobutyl GABA

Utility Application